ETNB(ETNB)
ETNB
ANALYST COVERAGE12 analysts
BUY
▼ -2.3%downside to target
L $12.00
Med $14.50consensus
H $25.00Key MetricsTTM
Market Cap$2.20B
Revenue TTM$21.0K
Net Income TTM-$450.21M
Free Cash Flow-$439.19M
Gross Margin-85.7%
Operating Margin-1493990.5%
Net Margin-1433966.7%
Return on Equity-59.1%
Return on Assets-49.9%
Debt / Equity0.07
Current Ratio15.19
EPS TTM$-1.91
PRICE
Prev Close
14.84
Open
14.84
Day Range—
52W Range4.16 – 15.06
4.16
15.06
98% of range
VOLUME & SIZE
Avg Volume
5.4M
FUNDAMENTALS
P/E Ratio
-4.0x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.72
Low vol
TECHNICAL
RSI (14)
77
Overbought
Upcoming Events
EEarnings Report
Tomorrow
May 24
DEx-Dividend
In 90 days
Aug 21
PDividend Pay
In 128 days
Sep 28
ETNB News
About
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Harry MansbachChief Medical Officer
Teresa PerneyChief Regulatory & Quality Officer
Francis W. SarenaChief Operating Officer
Michael BaldwinSenior Vice President & Head of Quality
Quoc Le-NguyenChief Technical Officer
Rohan PalekarChief Executive Officer & Director
Ryan Stephen MartinsChief Financial Officer
Shiva K. NatarajanSenior Vice President of Finance & Principal Accounting Officer
Amanda KuriharaVice President of People & Culture
Annie J. ChangVice President of Investor Relations & Corporate Communications
Melissa AbelSenior Vice President of Commercial Strategy